Endowment / Foundation

Updated:

Marianthi Foundation

The Marianthi Foundation was established in 1994 by P. Roy Vagelos and his wife Diana, formalizing a family philanthropic tradition anchored by the wealth Roy...

Marianthi Foundation logo

Marianthi Foundation

The Marianthi Foundation was established in 1994 by P. Roy Vagelos and his wife Diana, formalizing a family philanthropic tradition anchored by the wealth Roy Vagelos generated as CEO of Merck and later as Chairman of Regeneron Pharmaceuticals. Named after Roy Vagelos's mother, the foundation directs capital primarily toward university-level educational projects, biomedical research, and environmental causes, reflecting the family's scientific and academic values. While grantmaking defines its public identity, the foundation maintains an active investment posture concentrated in buyout strategies across multiple asset classes. A substantial portion of the foundation's balance sheet derives from P. Roy Vagelos's long-standing relationship with Regeneron, where he has served as Chairman and accumulated significant equity. The foundation is governed by a tight family board. Diana T. Vagelos serves as Vice President and Treasurer while also holding a trustee role at Barnard College. The next generation is represented through directors Andrew Vagelos and Cynthia Vagelos Roberts. P. Roy Vagelos's professional affiliations — including membership in the National Academy of Sciences and the American Academy of Arts and Sciences — extend the foundation's reach into elite scientific and institutional networks that can inform both grantmaking and investment sourcing. The structural differentiator is the fusion of a scientist-CEO's investment judgment with a grantmaking mission. Unlike many foundations that outsource investment decisions entirely to an OCIO, the Marianthi Foundation appears to blend direct buyout exposure, real assets, and private credit alongside concentrated public-company equity from Roy Vagelos's board-level corporate relationships. This hybrid posture — part family office, part institutional foundation — is unusual for a vehicle of its reported scale, and it ties the foundation's financial durability directly to Roy Vagelos's presence and Regeneron's trajectory.

General information

Firm type

Endowment / Foundation

Year founded

1994

Location

Region

North America

Country

United States

City

New York

Corporate office

New York, NY, United States

Principals

P. Roy Vagelos

Founder

Diana T. Vagelos

Vice President and Treasurer

Andrew Vagelos

Director

Cynthia Vagelos Roberts

Director

Sector focus

Pharmaceuticals & BiotechReal EstatePrivate Credit

Frequently asked questions

How is the Marianthi Foundation related to Regeneron Pharmaceuticals?

P. Roy Vagelos serves as Chairman of Regeneron, and the foundation holds significant Regeneron equity — making the biotech company's stock performance a material factor in the foundation's investment portfolio. This creates an unusually concentrated link between a single public company and a grantmaking foundation's balance sheet.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on endowments & foundations?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More New York Endowment / Foundation profiles